For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Elevated Serum Soluble CD30 Precedes the Development of AIDS-Associated Non-Hodgkin’s B Cell LymphomaBreen E.C.a · Fatahi S.b · Epeldegui M.b · Boscardin W.J.c · Detels R.d · Martínez-Maza O.a, b
Departments of aObstetrics and Gynecology and bMicrobiology, Immunology, and Molecular Genetics, David Geffen School of Medicine and Departments of cBiostatistics and dEpidemiology, School of Public Health, University of California, Los Angeles, Calif., USA
CD30, first described as the Ki antigen on malignant B cells in Hodgkin’s lymphoma, is also expressed on normal activated B and T cells. It can be cleaved from the cell surface and detected in normal serum as soluble CD30 (sCD30), where it can be an indicator of levels of immune activation. In a cross-sectional study utilizing archived sera at a time point close to but preceding a diagnosis of acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin’s B cell lymphoma, AIDS lymphoma subjects (n = 49) showed elevated mean levels of sCD30 compared to controls with AIDS but no malignancy (n = 44, p < 0.01), HIV-infected but relatively healthy (n = 47, p < 0.001), or HIV-seronegative controls (n = 44, p < 0.001). Serum sCD30 was significantly correlated to serum levels of the B cell cytokines interleukin-6 (IL-6), IL-10, and sCD23, but only among lymphoma subjects (p ≤ 0.05). Correlations between sCD30 and other markers of immune system activation were seen among all HIV-infected subjects (sCD27, sCD44, CXCL13, p < 0.05). These observations suggest that sCD30, especially in combination with other immune system molecules, could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma.
© 2006 S. Karger AG, Basel